Pacira Pharmaceuticals Inc. (PCRX)

47.00
NASDAQ : Health Technology
Prev Close 48.21
Day Low/High 46.71 / 48.36
52 Wk Low/High 26.95 / 52.60
Avg Volume 588.20K
Exchange NASDAQ
Shares Outstanding 40.96M
Market Cap 1.97B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANDE, BPI, CORE, ECHO, EPAY, FRD, HTBI, LAWS, MCY, MEDP, NMFC, NTES, PCRX, SCHL, SLG, SU, SWIR Downgrades: AKAM, AXU, DFRG, FFWM, IAG, IVC, MHK, RGNX, SRE, TARO, TWNK, UNFI, VECO Initiations: CGBD, SMHI, WTTR Read on to get TheStreet Quant Ratings' detailed report:

First Week Of February 2019 Options Trading For Pacira Pharmaceuticals (PCRX)

First Week Of February 2019 Options Trading For Pacira Pharmaceuticals (PCRX)

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the February 2019 expiration.

MEDNAX National Medical Group And Pacira Pharmaceuticals Launch National Enhanced Recovery After Cesarean Surgery (ERACS™) Collaborative To Minimize Opioid Use

MEDNAX National Medical Group And Pacira Pharmaceuticals Launch National Enhanced Recovery After Cesarean Surgery (ERACS™) Collaborative To Minimize Opioid Use

MEDNAX, Inc. (NYSE:MD), the national health solutions partner specializing in anesthesiology, neonatology, maternal-fetal medicine, other pediatric services, radiology and management services, is pleased to announce that it has partnered with Pacira...

Interesting PCRX Put And Call Options For June 15th

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the June 15th expiration.

University Of Tennessee Medical Center At Knoxville, Pacira Pharmaceuticals, And CQ-Insights Announce Collaboration To Minimize Opioid Use After Hernia Surgery

University Of Tennessee Medical Center At Knoxville, Pacira Pharmaceuticals, And CQ-Insights Announce Collaboration To Minimize Opioid Use After Hernia Surgery

Continuous quality improvement project aims to optimize patient outcomes after hernia repair

Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee To Review SNDA For EXPAREL® As A Nerve Block For Regional Analgesia

Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee To Review SNDA For EXPAREL® As A Nerve Block For Regional Analgesia

Anesthetic and Analgesic Drug Products Advisory Committee Meeting February 14-15

First Week of March 16th Options Trading For Pacira Pharmaceuticals (PCRX)

First Week of March 16th Options Trading For Pacira Pharmaceuticals (PCRX)

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the March 16th expiration.

WellStar Health System And Pacira Pharmaceuticals Announce Partnership To Minimize Opioid Use And Standardize Outcomes Across Surgical Procedures

WellStar Health System And Pacira Pharmaceuticals Announce Partnership To Minimize Opioid Use And Standardize Outcomes Across Surgical Procedures

Agreement will focus on designing and deploying best practice enhanced recovery protocols across therapeutic areas in 11 Georgia-based hospitals

First Week Of PCRX August 2018 Options Trading

First Week Of PCRX August 2018 Options Trading

Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the August 2018 expiration.

Illinois Surgical Quality Improvement Collaborative And Pacira Pharmaceuticals, Inc. Announce Collaboration To Minimize Opioid Exposure For Postsurgical Patients

Illinois Surgical Quality Improvement Collaborative And Pacira Pharmaceuticals, Inc. Announce Collaboration To Minimize Opioid Exposure For Postsurgical Patients

Collaboration will develop and distribute evidence-based strategies, education and resources to reduce the overprescribing and optimize the use of opioids across 56 Illinois hospitals

Pacira Announces Promotions Of Scott Braunstein, MD, To Chief Operating Officer And Richard Scranton, MD, To Chief Scientific Officer

Pacira Announces Promotions Of Scott Braunstein, MD, To Chief Operating Officer And Richard Scranton, MD, To Chief Scientific Officer

Expanded roles reflect key accomplishments and demonstrated leadership

Interesting PCRX Put And Call Options For January 2018

Interesting PCRX Put And Call Options For January 2018

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the January 2018 expiration.

Pacira Pharmaceuticals And TELA Bio Announce Equity Agreement

Pacira Pharmaceuticals And TELA Bio Announce Equity Agreement

Pacira to invest up to $25 million in TELA Bio to enhance commercial and clinical initiatives for distinct class of novel surgical implants for soft tissue repair

TheStreet Quant Rating: C (Hold)